Search

Your search keyword '"Lippe Ralph"' showing total 38 results

Search Constraints

Start Over You searched for: Author "Lippe Ralph" Remove constraint Author: "Lippe Ralph"
38 results on '"Lippe Ralph"'

Search Results

12. Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis

13. MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis

14. Differential properties of Janus kinase inhibitors in the treatment of immune-mediated inflammatory diseases.

18. A review of JAK-STAT signalling in the pathogenesis of spondyloarthritis and the role of JAK inhibition

19. Effect of upadacitinib on reducing pain in patients with active psoriatic arthritis or ankylosing spondylitis: post hoc analysis of three randomised clinical trials

20. Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials

22. Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study

23. review of JAK–STAT signalling in the pathogenesis of spondyloarthritis and the role of JAK inhibition.

24. Treatment Mode Preferences in Psoriatic Arthritis: A Qualitative Multi-Country Study

28. Long-term efficacy and safety analysis of tofacitinib in the treatment of rheumatoid arthritis in a Western European subpopulation

30. Nicht-interventionelle Studie (NIS) zur routinemäßigen Anwendung von Enbrel® (Etanercept) bei der Behandlung von Patienten mit Ankylosierender Spondylitis (AS) über 52 Wochen: Eine Evaluierung patientenrelevanter und gesundheitsökonomischer Parameter

31. Immune Suppression via Glucocorticoid-Stimulated Monocytes: A Novel Mechanism To Cope with Inflammation

34. The Cyclic AMP Response Element Modulator α Suppresses CD86 Expression and APC Function

36. Association Between Achievement of Clinical Disease Control and Improvement in Patient-Reported Outcomes and Quality of Life in Patients With Psoriatic Arthritis in the Phase 3 SELECT-PsA 1 and 2 Randomized Controlled Trials.

37. A review of JAK-STAT signalling in the pathogenesis of spondyloarthritis and the role of JAK inhibition.

38. The cyclic AMP response element modulator {alpha} suppresses CD86 expression and APC function.

Catalog

Books, media, physical & digital resources